A Phase 1/2 interventional study of Gemcitabine + BCG and BCG (TICE strain) in NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma and Bladder (Urothelial, Transitional Cell) Cancer, sponsored by Queen's University. Not yet recruiting at 1 site in Canada. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Queen's University · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms — 11 open to participants now, 16 under way, 3 of them phase 3. Gemcitabine · Non-Muscle Invasive Bladder Neoplasms.
Among the 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms, this one is the 17th largest by planned enrollment, is one of 4 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 4 of the 15 other live ones, and was the 18th registered.
294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.
Browse Non-Muscle Invasive Bladder Neoplasms studies →11 of the 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Ferring Pharmaceuticals · Sites in United States, Canada, Czechia and 5 more countries
Ages 18+
Relmada Therapeutics, Inc. · Sites in Israel
Ages 18–80
Ekaterina Laukhtina · Sites in Austria
Ages 18+
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 3 · Phase 4 1
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 31 is below the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.
Median enrollment 70 across the 20 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 20 have an industry lead sponsor. The 10 most frequent:
Queen's University is the lead sponsor of 207 studies on the registry; 15 are open to participants now.
Queen's University has 1 study filed under Non-Muscle Invasive Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06829823ImmunityBio, Inc.Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | 2026-11 |
| NCT07064863Queen's UniversityA Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. | 2027-07-31 |
| NCT07189793First Affiliated Hospital of Wenzhou Medical UniversityToripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study | 2027-10 |
| NCT06663137Relmada Therapeutics, Inc.A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC | 2027-11 |
| NCT04179162Memorial Sloan Kettering Cancer CenterBacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment | 2027-11 |
Add all 6 to your calendar (.ics) → With an account.
Among the 20 studies testing gemcitabine in Non-Muscle Invasive Bladder Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to establish a novel tumor tissue- and blood-based biomarker test to assess early systemic and local response to immunomodulation by BCG immunotherapy in patients with high-risk non-muscle invasive bladder cancer. Responses will be compared between patients with high-risk NMIBC who are being treated with standard of care BCG therapy and those treated with combination chemotherapy. Local and systemic immune monitoring assays will allow early identification of patients who will not benefit from BCG immunotherapy.
BCG immunotherapy is the current gold standard for NMIBC. However, \~50% of patients will eventually experience recurrence or progression. Pre-treatment immune competence of the patient, the bladder microenvironment and systemic immune responses to immunomodulation by BCG govern effectiveness. The investigators intend to utilize a novel tumor tissue and blood based biomarker test to assess early systemic responses to standard of care BCG based immunotherapy as well as alternate strategies to enhance immune responses as measured systemically as well as based on early response rates (3 month complete response or 3 month recurrence). The goal of this study is to develop strategies to identify novel more effective anti-tumor immune responses for NMIBC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be recruited to treatment with gemcitabine at week 0 following which BCG (50 mg, TICE strain) will be administered once every week for a total of 5 instillations.
Drug: Gemcitabine + BCG
6 intravesical instillations of BCG (50 mg, TICE strain) at weekly intervals.
Drug: BCG (TICE strain)
Drug pages: GemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BCG VaccineStudies of BCG VaccineBCG Vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients will receive a single intravesical instillation of gemcitabine (2000 mg) at week 0 followed by weekly BCG (50 mg of TICE strain) for a total of 5 instillations. Biopsy will be conducted within three months of completing the induction phase.
Patients will receive intravesical BCG (50 mg, TICE strain) at weekly intervals for a total of 6 instillations. Biopsy will be performed within 3 months of completing the induction phase.
BCG ImmunoScore
Complete response at 3 months with no evidence of tumor recurrence as assessed by biopsy. Demonstrable immunological responses measured at weeks 2, and 5 post-treatment, based on a novel tissue and blood based immune biomarker.
Time frame: 3 months
Recurrence free survival
Recurrence free survival at 12 months post treatment initiation.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Jul 2027, 23 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · BCG Vaccine
Non-Muscle Invasive Bladder Neoplasms →